Share

Billions for Hungarian biotech company


The Spanish diagnostics group Werfen is acquiring the Hungarian company Omixon for around 25 million US dollars.

The Barcelona-based group has finalised the acquisition of the Hungarian company Omixon after receiving all the necessary regulatory approvals, reported the Hungarian edition of the business magazine Forbes. Omixon Biocomputing Kft. was founded in 2011 by Attila Bérces and has developed from a software developer for genetics into a specialist for sequencing technologies (NGS) used in transplant diagnostics.

Renowned investors

Several venture capitalists were involved in financing the company, including Fastventures Zrt. and Lochlomond Holding as well as Euroventures. Márton Szőke has already helped several Hungarian start-ups to success as an investor. He was involved in Tresorit, which Swiss Post acquired three years ago for 47 million Swiss francs, and has recently invested in Bitrise and Recart.

Strong growth during corona

The company recorded strong growth in 2020 thanks to the development of a novel coronavirus test. The viral RNA detection directly from the heat-treated sample made the test faster and more efficient. In 2020, the company generated 35-40% of its turnover of 2.5 billion forints with this test, compared to 1.6 billion forints in 2023. For founder Attila Bérces, the merger with Werfen marks an exciting new chapter in strengthening the company’s global presence. The buyer Werfen, with technology centres in the USA and Europe, has an annual turnover of over 2 billion US dollars and employs more than 5,000 people.

 



Source link